Page 121 - 2018_11-Haematologica-web

Genetics and outcomes in AML patients ≥75 years
nous leukemia with a normal karyotype.
Blood. 2005;106(12):3733-3739.
23. Kiyoi H, Naoe T, Yokota S, et al. Internal
tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia. 1997;11(9):1447-1452.
24. Benthaus T, Schneider F, Mellert G, et al. Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia. Br J Haematol. 2008;143(2):230-239.
25. Krug U, Berdel WE, Gale RP, et al. Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia. Leukemia. 2016;30(6):1230-1236.
26. Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477-2487.
27. Jaiswal S, Fontanillas P, Flannick J, et al. Age- related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488-2498.
28. Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079-1089.
29. Kihara R, Nagata Y, Kiyoi H, et al. Comprehensive analysis of genetic alter- ations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia. 2014;28(8):1586-1595.
30. Nazha A, Ravandi F. Acute myeloid leukemia in the elderly: do we know who should be treated and how? Leuk Lymphoma. 2014;55(5):979-987.
31. Heiblig M, Le Jeune C, Elhamri M, et al. Treatment patterns and comparative effec- tiveness in elderly acute myeloid leukemia patients (age 70 years or older): the Lyon- university hospital experience. Leuk
Lymphoma. 2017;58(1):110-117.
32. Bullinger L, Dohner K, Dohner H. Genomics of acute myeloid leukemia diagnosis and pathways. J Clin Oncol. 2017;35(9):934-946. 33. Silva P, Neumann M, Schroeder MP, et al. Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epi- genetic landscape. Leukemia. 2017;31(7):
1640-1644.
34. Xu Q, Li Y, Lv N, et al. Correlation between
isocitrate dehydrogenase gene aberrations and prognosis of patients with acute myeloid leukemia: a systematic review and meta-analysis. Clin Cancer Res. 2017;23(15): 4511-4522.
35. Green CL, Evans CM, Hills RK, Burnett AK, Linch DC, Gale RE. The prognostic signifi- cance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood. 2010;116(15):2779-2782.
36. DiNardo CD, Ravandi F, Agresta S, et al. Characteristics, clinical outcome, and prog- nostic significance of IDH mutations in AML. Am J Hematol. 2015;90(8):732-736.
37. Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010;28(22):3636-3643.
38. Yamaguchi S, Iwanaga E, Tokunaga K, et al. IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 muta- tion. Eur J Haematol. 2014;92(6):471-477.
39. Boissel N, Nibourel O, Renneville A, et al. Prognostic impact of isocitrate dehydroge- nase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. J
Clin Oncol. 2010;28(23):3717-3723.
40. Abbas S, Lugthart S, Kavelaars FG, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberra- tions in acute myeloid leukemia: prevalence and prognostic value. Blood. 2010;116(12):
2122-2126.
41. Figueroa ME, Abdel-Wahab O, Lu C, et al.
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553- 567.
42. Im AP, Sehgal AR, Carroll MP, et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malig- nancies: associations with prognosis and potential treatment strategies. Leukemia. 2014;28(9):1774-1783.
43. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytoge- netic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5):1312-1320.
44. Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291-299.
45. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open- label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytara- bine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670-2677.
46. Wei AH, Tiong IS. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML. Blood. 2017;130(23):2469-2474.
haematologica | 2018; 103(11)
1861